UNMC & Longevity Biotech Publish Novel Neurodegenerative Diagnostic Imaging Approach for Parkinson’s Disease Using LBT-3627

UNMC & Longevity Biotech Publish Novel Neurodegenerative Diagnostic Imaging Approach for Parkinson’s Disease Using LBT-3627 - Longevity Biotech Skip to main content Hit enter to search or ESC to close Close Search Newsroom UNMC & Longevity Biotech Publish Novel Neurodegenerative Diagnostic Imaging Approach for Parkinson’s Disease Using LBT-3627 By kappNo Comments Vasoactive intestinal peptide (VIP) mediates a broad range of biological responses by activating two related receptors, VIP receptor 1 and 2 (VIPR1 and VIPR2). Although the use of native VIP facilitates neuroprotection, clinical application of the hormone is limited due to VIP’s rapid metabolism and inability to distinguish between VIPR1 and VIPR2 receptors. Click here to read more. Privacy Policy  |  Cookies Policy  |  Terms & Conditions linkedin © 2026 Longevity Biotech. All Rights Reserved Close Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM CONTACT linkedin

The release as fetched from its publisher. longevitybiotech.com ↗